- $482.93m
- $210.77m
- $200.45m
- 88
- 47
- 53
- 67
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.22 | ||
| Price to Tang. Book | 1.35 | ||
| Price to Free Cashflow | 22.31 | ||
| Price to Sales | 2.41 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -4.75% | ||
| Return on Equity | -1.53% | ||
| Operating Margin | -10.24% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 92.84 | 127.95 | 164.04 | 193.01 | 200.45 | 204.43 | 221.75 | 28.2% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | -94.14 | +1190.97 | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Cytek Biosciences, Inc. is a cell analysis solutions company. The Company is advancing the cell analysis tools by delivering high-resolution, high-content, and high-sensitivity cell analysis utilizing its patented Full Spectrum Profiling (FSP) technology. Its platform includes its core FSP instruments, the Cytek Aurora and Northern Lights systems and the Cytek Aurora CS cell sorter; the Cytek Orion reagent cocktail preparation system; the Enhanced Small Particle (ESP) detection technology; the flow cytometer and imaging products under the Amnis and Guava brands, and reagents, software and service to provide a comprehensive and integrated suite of solutions for its customers. Its Cytek Aurora and Northern Lights systems are used in the study of infectious diseases, immunology, immunotherapy, immuno-oncology, oncology, and drug discovery. The Cytek Orion reagent cocktail preparation system enables researchers to fully automate the preparation of antibody cocktails for flow cytometry.
Directors
- Wenbin Jiang PRE (57)
- Ming Yan CFD (58)
- Patrik Jeanmonod CFO (55)
- Allen Poirson SVP (61)
- Valerie Barnett GCN (46)
- Ken Riley GMG
- Jack Ball IND (74)
- Tess Cameron IND (35)
- Feng Deng IND (57)
- Gisele Dion IND (54)
- Vera Imper IND
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- December 15th, 2014
- Public Since
- July 23rd, 2021
- No. of Shareholders
- 18
- No. of Employees
- 648
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
NASDAQ Global Select Market- Shares in Issue
- 128,097,379
- Address
- 47215 LAKEVIEW BOULEVARD, FREMONT, 94538
- Web
- https://cytekbio.com
- Phone
- Auditors
- Deloitte & Touche LLP
Upcoming Events for CTKB
Q1 2025 Cytek Biosciences Inc Earnings Call
Cytek Biosciences Inc Annual Shareholders Meeting
Q2 2025 Cytek Biosciences Inc Earnings Release
Similar to CTKB
10X Genomics
NASDAQ Global Select Market
Accuray
NASDAQ Global Select Market
Akoya Biosciences
NASDAQ Global Select Market
Align Technology
NASDAQ Global Select Market
Alphatec Holdings
NASDAQ Global Select Market
FAQ
What is the Cytek Biosciences share price?
As of Today at 20:08 UTC, shares in Cytek Biosciences are trading at $3.77. This share price information is delayed by 15 minutes.
How has the Cytek Biosciences share price performed this year?
Shares in Cytek Biosciences last closed at $3.77 and the price had moved by -33.04% over the past 365 days. In terms of relative price strength the Cytek Biosciences share price has underperformed the S&P500 Index by -38.19% over the past year.
What are the analyst and broker recommendations for Cytek Biosciences?
The overall consensus recommendation for Cytek Biosciences is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Cytek Biosciences dividend yield?
Cytek Biosciences does not currently pay a dividend.
Does Cytek Biosciences pay a dividend?
Cytek Biosciences does not currently pay a dividend.
When does Cytek Biosciences next pay dividends?
Cytek Biosciences does not currently pay a dividend.
How do I buy Cytek Biosciences shares?
To buy shares in Cytek Biosciences you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Cytek Biosciences?
As of the previous close price of $3.77, shares in Cytek Biosciences had a market capitalisation of $482.93m.
Where are Cytek Biosciences shares listed?
Here are the trading details for Cytek Biosciences:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: CTKB
What kind of share is Cytek Biosciences?
Based on an overall assessment of its quality, value and momentum Cytek Biosciences is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Cytek Biosciences share price forecast for 2025?
The analyst consensus target price for shares in Cytek Biosciences is $6.70. That is 77.72% above the last closing price of $3.77.
Analysts covering Cytek Biosciences currently have a consensus Earnings Per Share (EPS) forecast of -$0.06 for the next financial year.
Find out moreWhat is the trend in the Cytek Biosciences share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Cytek Biosciences. Over the past six months, its share price has underperformed the S&P500 Index by -15.28%.
As of the last closing price of $3.77, shares in Cytek Biosciences were trading -30.71% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Cytek Biosciences PE Ratio?
The Cytek Biosciences PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $3.77.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Cytek Biosciences?
Cytek Biosciences' management team is headed by:
- Wenbin Jiang - PRE
- Ming Yan - CFD
- Patrik Jeanmonod - CFO
- Allen Poirson - SVP
- Valerie Barnett - GCN
- Ken Riley - GMG
- Jack Ball - IND
- Tess Cameron - IND
- Feng Deng - IND
- Gisele Dion - IND
- Vera Imper - IND